eligibility_summary
Eligible patients: 14–75, hematologic malignancy post allo‑HSCT with EBV+, KPS ≥70 (≥16y) or Lansky ≥50 (<16y). Donor: 8–70, consented, ≥3/6 HLA match, lymphocytes 0.8–4×10^9/L, adequate veins. Exclude: uncontrolled aGVHD, severe renal/hepatic dysfunction or NYHA IV HF, planned steroids at infusion, other/relapsed uncontrolled cancers, HIV‑Ab/TAP‑ab+, pregnant/lactating, other cell therapy ≤4 wks, other trials ≤30 days.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
manual_review_required
ai_summary
Intervention: EBV‑TCR‑T cells (biological, gene‑modified adoptive T‑cell therapy). Mechanism: Donor T cells are lentivirally transduced to express an EBV‑specific, HLA‑A02:01/11:01/24:02‑restricted T‑cell receptor. On recognizing EBV peptides presented on class I HLA, engineered T cells activate via TCR signaling to kill targets (perforin/granzyme) and secrete cytokines. Dosing: 0.5–1.0×10^6 cells/kg, 1–3 infusions. Targets: EBV‑infected cells after allogeneic HSCT—primarily EBV‑harboring lymphocytes/B cells—via antigen presentation pathways (HLA class I) to restore EBV‑specific cytotoxic T‑cell immunity, study assesses safety, efficacy, PK, and cytokines. Status: Phase 1, single‑arm, multicenter (China).